Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Piperocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.95 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.95 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.95 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperocaine SCHEMBL9224611 | 1.00 | SCN1A (0.95) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL25714 | 0.98 | SCN1A (1.00) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL25713 | 0.98 | SCN1A (1.00) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL503030 | 0.96 | SCN1A (0.98) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL503032 | 0.96 | SCN1A (0.98) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Piperocaine SCHEMBL7615890 | 0.93 | SCN1A (0.91) | SCN1ASCN2ASCN3ACHRNB2CHRNA5 | |
| Biphenyl SCHEMBL23174836 | 0.82 | SCN1A (0.72) | SCN1ASCN2ASCN3AHRH3HRH2 | |
| Cyclomethycaine SCHEMBL25345 | 0.82 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL25346 | 0.82 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634211 | 0.81 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0682942-A1 | NOVEL, PERCUTANEOUSLY ABSORBABLE PREPARATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-11-22 | — | — | EP | disclosed |
| US-4863952-A | Method of promoting percutaneous drug absorption with 2-pyrrolidin-2-one 5-carboxylic acids and esters thereof | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| US-4847260-A | NICOTINIC AND ISONITINIC ESTER ANTIARRHYTHMIA AGENTS FOR SKINS | NITTO DENKO CORPORATION (JP) | 1989-07-11 | — | — | US | disclosed |
| EP-0182635-B1 | COMPOSITION FOR PERCUTANEOUS ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0182635-A1 | Composition for percutaneous administration | NITTO DENKO CORPORATION (JP) | 1986-05-28 | — | — | EP | disclosed |